MPLT MapLight Therapeutics Inc revenue, earnings and financials
For the quarter ended June 30, 2026, MapLight Therapeutics Inc reported revenue of n/a, net income of −$60.2M and diluted EPS of −$1.32; for the fiscal year ended December 2025 revenue was n/a.
MPLT annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$169M, net income −$161M (margin n/a), EPS −$18.56
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$82.9M, net income −$77.6M (margin n/a), EPS −$105.38
MPLT quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$60.2M, EPS −$1.32
- Quarter ended Mar 31, 2026: revenue n/a, net income −$60.7M, EPS −$1.34
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$79.5M, EPS $87.06
- Quarter ended Sep 30, 2025: revenue n/a, net income −$29.4M, EPS −$37.18
- Quarter ended Jun 30, 2025: revenue n/a, net income −$29.8M, EPS −$39.11
- Quarter ended Mar 31, 2025: revenue n/a, net income −$22.3M, EPS −$29.33
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$21.2M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$19.0M, EPS −$25.08
- Quarter ended Jun 30, 2024: revenue n/a, net income −$18.4M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$18.9M, EPS n/a
MPLT cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$138M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$78.8M, share buybacks n/a
MPLT balance sheet
- Jun 30, 2026: cash $71.6M, total assets $368M, total liabilities $20.0M, shareholders' equity $348M
- Mar 31, 2026: cash $55.7M, total assets $419M, total liabilities $19.0M, shareholders' equity $400M
- Dec 31, 2025: cash $46.7M, total assets $480M, total liabilities $21.1M, shareholders' equity $458M
- Sep 30, 2025: cash $64.1M, total assets $257M, total liabilities $23.7M, shareholders' equity −$274M
- Dec 31, 2024: cash $38.3M, total assets $137M, total liabilities $21.7M, shareholders' equity −$194M
Is MPLT profitable?
No. MapLight Therapeutics Inc lost $230M over the last four quarters.
What is MPLT's EPS?
Diluted earnings per share over the last four quarters were $47.22; −$1.32 in the latest quarter.